These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 19121408)
21. Biotech companies adapt to big pharma mergers. Niiler E Nat Biotechnol; 2000 May; 18(5):487-8. PubMed ID: 10802607 [No Abstract] [Full Text] [Related]
22. In search of sustainability: process R&D in light of current pharmaceutical industry challenges. Federsel HJ Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405 [TBL] [Abstract][Full Text] [Related]
23. Hidden in plain view. Jacobs T Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141 [No Abstract] [Full Text] [Related]
24. UK industry consolidation is slow despite big merger. Mitchell P Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553 [No Abstract] [Full Text] [Related]
25. Overcoming the obstacles in the pharma/biotech industry: 2009 update. Graul AI; Revel L; Tell M; Rosa E; Cruces E Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219 [TBL] [Abstract][Full Text] [Related]
26. Mastering the value chain. An interview with Mark Levin of Millennium Pharmaceuticals. Interview by David Champion. Levin M Harv Bus Rev; 2001 Jun; 79(6):108-15, 148. PubMed ID: 11408971 [TBL] [Abstract][Full Text] [Related]
27. Building deals on bedrock. Harding D; Rovit S Harv Bus Rev; 2004 Sep; 82(9):121-8, 138. PubMed ID: 15449861 [TBL] [Abstract][Full Text] [Related]
31. [The United States-European Union Transatlantic Trade and Investment Partnership and its possible effects on the Spanish health system]. Navarro V Gac Sanit; 2015; 29(5):326-7. PubMed ID: 26068812 [No Abstract] [Full Text] [Related]
32. Can complexity be commercialized? Mack GS Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456 [No Abstract] [Full Text] [Related]
33. Big pharma slims down to bolster productivity. Owens J Nat Rev Drug Discov; 2007 Mar; 6(3):173-4. PubMed ID: 17396286 [No Abstract] [Full Text] [Related]
34. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Dierks RM; Bruyère O; Reginster JY; Richy FF Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):571-578. PubMed ID: 27653356 [TBL] [Abstract][Full Text] [Related]
35. A new prescription for your portfolio. Clifford L; O'Keefe B; Stires D Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357 [No Abstract] [Full Text] [Related]
37. Biotech acquisitions by big pharma: why and what is next. Malik NN Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004 [TBL] [Abstract][Full Text] [Related]
38. Can science be a business? Lessons from biotech. Pisano GP Harv Bus Rev; 2006 Oct; 84(10):114-24, 150. PubMed ID: 17040044 [TBL] [Abstract][Full Text] [Related]
39. A better prescription for drug-development financing. Kessel M; Frank F Nat Biotechnol; 2007 Aug; 25(8):859-66. PubMed ID: 17687358 [No Abstract] [Full Text] [Related]